The proof-of-concept studies here are consistent with a mechanism of action whereby REDD1 drives renal injury by promoting GSK3β-dependent NF-κB activation in podocytes, thereby enhancing the renal pro-inflammatory immune response to diabetes. Here, NFKB1 is linked to diabetes mellitus.